Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results

[In The News]

TARRYTOWN, N.Y., Feb. 6, 2019 /PRNewswire/ -- Fourth quarter 2018 revenues were $1.93 billion, an increase of 22% Fourth quarter 2018 EYLEA® (aflibercept) Injection U.S. net sales increased 11% to $1.08 billion versus fourth quarter 2017 Fourth quarter 2018 Libtayo® (cemiplimab-rwlc)...

View the full article